Rhythm Biosciences Ltd has released a press release.
Prospectus - 2024 Non-Renounceable Rights Issue
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
In the deck
Earlier from Rhythm Biosciences
- Rights Issue Offer to Raise Up To $6.6 million
- Quarterly Activities Report and Appendix 4C - Dec23
- Strategy & Market Update
- Platform Expansion - Lung Cancer Diagnostic Test Update
- Executive Management Changes
Later from Rhythm Biosciences
- Half Yearly Report and Accounts
- S&P DJI Announces March 2024 Quarterly Rebalance
- Internationally Renowned Clinical Advisory Board Established
- Close of Rights Issue
- Rhythm Maintains ISO Certification
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences